|Articles|September 22, 2016
Calvo Elected for Second Term at EMA
Author(s)Philip Ward
Dr. Gonzalo Calvo has been re-elected by the Healthcare Professionals’ Working Party (HCPWP) of the European Medicines Agency (EMA) as its co-chair.
Advertisement
The Healthcare Professionals' Working Party (HCPWP) of the European Medicines Agency (EMA) has re-elected Dr. Gonzalo Calvo as its co-chair.
Calvo, a physician and consultant in clinical pharmacology from Barcelona, Spain, has extensive experience in medicines regulation, including nearly 10 years as a member of EMA’s Committee for Medicinal Products for Human Use (CHMP).
“My aim is to consolidate the work initiated and open new paths to strengthen the role and impact of healthcare professionals in regulatory activities, securing fast and safe access to new medicines,” said Calvo. “Close collaboration with the patients and consumers’ working group has been instrumental for the progress of HCPWP work. I do not see any other way forward than enhancing our interaction with patients and consumers.”
Together with Isabelle Moulon, Head of the Public Engagement Department at EMA, he will co-chair HCPWP for the next three years.
No decision was reached, however, on the new co-chair of the Patients' and Consumers' Working Party (PCWP).
The main role of the PCWP and the HCPWP is to provide recommendations to EMA and its scientific committees on all matters of interest to either patients and consumers or healthcare professionals in relation to medicines, as well as to monitor interactions between the agency and patients, consumers and healthcare professionals.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Ensuring Digital Trial Platforms Work for Underserved Communities
September 10th 2025
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
2
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
3
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
4
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
5